Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID‐19 Epidemic

The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID‐19) revived the interest in its cardiac toxicity, increasingly sidelined over time. We aimed to assess and compare the profile of cardiac adverse drug reactions (CADRs) associated with HCQ before and during COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Romani, Serena, Gérard, Alexandre, Fresse, Audrey, Viard, Delphine, Van‐Obberghen, Élise, Micallef, Joëlle, Rocher, Fanny, Drici, Milou‐Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877831/
https://www.ncbi.nlm.nih.gov/pubmed/32964653
http://dx.doi.org/10.1111/cts.12883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877831/
https://www.ncbi.nlm.nih.gov/pubmed/32964653
http://dx.doi.org/10.1111/cts.12883

Ejemplares similares